Regulatory writings
Clinical Study ReportCTD Module 2 DossierClinical Protocol & SAPInvestigator BrochureDevice Clinical (CER)IVD Performance (PER)Risk Management PlanDSUR & PSUR Reports
Source-grounded medical writing you can defend.
Turn client inputs and literature into a traceable draft where every claim is linked to its source.
Book a call
Private. No model training.
Watch Demo
See 7Scholar in action
One workspace. All deliverables.
All deliverables in one workspace.
For diverse and source-heavy medical communications.
Publications
Primary trial manuscriptNarrative review articleRWE manuscriptSecondary/Ad-hoc manuscriptCongress abstract & posterPlain language summary
Medical affairs
Core scientific narrativeAd board briefing bookAd board summary reportMSL slide decksStandard response doc (SRD)Objection handlersMedical information letters
Draft · Verify · Defend
A defensible draft with evidence attached.
Every claim stays connected to the supporting evidence or literature.
Draft
Combination therapy reduced mortality (HR, 0.68; 95% CI, 0.57–0.80) versus ADT alone. Overall survival was the primary endpoint. Consistent with earlier docetaxel evidence.1
TFL.xlsxVerified
Table 14.2 · row 22
HR 0.68 (0.57–0.80)
Overall survival — hazard ratio 0.68 (95% CI, 0.57–0.80); P<0.001.
Source link
Protocol.docxVerified
§8.1 Endpoints
The primary endpoint was overall survival, defined as the time from randomization to death from any cause.
Source link
Smith MR, et al. N Engl J Med. 2022Verified
Reference 1
Darolutamide plus androgen-deprivation therapy and docetaxel significantly increased overall survival versus placebo.
Publication citation
Security & Privacy
Confidential by default. protected by design.
Your data remains isolated to your workspace and never used to train models.
Your work never trains a model.
Not ours, and not the model providers'. Your sources, project instructions, and drafts stay yours alone, so you can use 7Scholar with confidential material without giving it away.
No model trainingEU data stored in the EEA
GDPR Compliant
For all EU users, data is stored within the European Economic Area under the GDPR. AI processing runs through contracted providers, which may operate outside the EEA under appropriate safeguards.
Private to your workspace
Authentication, authorization, and workspace-level controls keep project material separated and available only to your authorized users.
Deletion you can rely on
After account deletion, your account and document data is purged within 30 days. AI providers we use for processing may retain data under their own contractual terms — for example, Google's terms allow up to roughly 7 months for a deletion instruction to complete.
How it works?
7Scholar functionalities
Approve plan before drafting
Review, edit, reorder, then approve or reject the proposed structure before drafting.
Review draft structure
Ready for reviewPlanned content
Burden of metastatic hormone-sensitive prostate cancer
Patterns of progression on androgen-deprivation therapy
Need for earlier treatment intensification
Planned content
Androgen-deprivation therapy as the treatment backbone
Survival benefit with docetaxel and androgen-receptor inhibitors
Remaining uncertainty around combination strategies
Planned content
Phase 3, randomized, double-blind trial design
Participating centers and enrollment period
Ethics, oversight, and informed consent
Planned content
Eligibility criteria and baseline disease characteristics
Randomization and assigned treatment regimens
Dose modifications, discontinuations, and follow-up
Planned content
Overall survival as the primary endpoint
Secondary efficacy and safety endpoints
Prespecified Cox model and sensitivity analyses from SAP.pdf
Planned content
Scheduled clinical assessments and imaging
Central review and data-quality procedures
Independent safety monitoring throughout the trial
Planned content
Randomized and treated populations
Baseline demographic and disease characteristics
Treatment exposure and reasons for discontinuation
Planned content
Overall survival from TFL.xlsx
Hazard ratio, confidence interval, and event rates
Consistency across prespecified subgroups
Planned content
Overall and grade 3–4 adverse events
Serious events and treatment discontinuations
Events of special clinical interest
Planned content
Quality-of-life scores over time
Time to pain progression and symptom burden
Completion rates for patient-reported assessments
Planned content
Survival benefit with treatment intensification
Consistency of benefit across patient subgroups
Balance between efficacy and tolerability
Planned content
Findings in the context of ARASENS and CHAARTED
Implications for first-line treatment selection
Relevance across disease volume and risk groups
Edit and write with AI
Command AI to write and edit in a Word-like document alongside you.
Draft
Results
Darolutamide reduced the risk of death by 32% versus placebo (hazard ratio, 0.68; 95% CI, 0.57–0.80), with 4-year overall survival of 62.7% and 50.4%, respectively.
AI Assistant
Proposed revision:
At 4 years, overall survival was 62.7% with darolutamide and 50.4% with placebo. The hazard ratio for death was 0.68 (95% CI, 0.57–0.80), indicating a lower risk of death with darolutamide.
Darolutamide reduced the risk of death by 32% versus placebo (hazard ratio, 0.68; 95% CI, 0.57–0.80), with 4-year overall survival of 62.7% and 50.4%, respectively.
Darolutamide reduced the risk of death by 32% versus placebo (hazard ratio, 0.68; 95% CI, 0.57–0.80), with 4-year overall survival of 62.7% and 50.4%, respectively.
Describe the revision...
Follow established guidelines
Review 7Scholar's suggested reporting guideline, or upload your own.
Darolutamide Phase 3 trial
Journal manuscript
Activate a guideline to apply it to your draft
Find supporting papers
Review supporting literature 7Scholar finds and screens, then add approved papers to your project.
Searching PubMed, PMC, ClinicalTrials.gov & project sources
80 papers found · 30 relevant matches selected
Supporting papers
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer
Smith et al. · NEJM · 2022Strong match
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
Chi et al. · NEJM · 2019Strong match
Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Mori et al. · Eur Urol · 2023Relevant
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Fizazi et al. · NEJM · 2017Relevant
Manage references
Import your EndNote library for drafting, then export to Word with native EndNote citations.
EN
EndNote
Team library
7Scholar
Project library
Project references
DeduplicatedDarolutamide and Survival in Metastatic Prostate Cancer
Smith et al. · 2024
Triplet Therapy for Metastatic Hormone-Sensitive Disease
Mori et al. · 2023
Treatment Intensification in Advanced Prostate Cancer
Chi et al. · 2022
Who's in control?
The medical writer is in control
7Scholar accelerates the work without taking over the judgment.
Medical writer
You decide what good looks like.
7Scholar follows.
Evidence
You choose the resourses.
7Scholar keeps every claim tied to them.
Draft
You set the message, structure, and level of scientific detail. 7Scholar drafts to your brief.
Review & deliver
You approve the structure and every change done under your direction.
Frequently Asked Questions
Everything medical writers need to know
Evidence stays inspectable
The writer approves the work
Your data is not used for training
7Scholar keeps the project connected from evidence intake through delivery: bring together papers and client materials, organize and inspect sources, shape the document, develop a cited draft, review claims against their evidence, and move the finished work to Word with its references.
Claims stay connected to their supporting evidence. You can inspect the cited paper passage or the relevant location in project material such as a protocol, SAP, or TFL, then decide whether the wording is accurate, appropriately qualified, and ready to keep.
7Scholar grounds drafting in the sources you select and makes the evidence trail visible, so the writer can challenge, edit, and approve every final claim. Scientific judgment and final sign-off remain with the team.
Your project data stays private and is not used for model training. Because client and sponsor policies differ, you should still follow the data-handling rules for each engagement. We can review 7Scholar's security and data practices with you or your team before a live project.
You can work from the mixed source packs medical writers actually receive, including journal articles, Word files, PDFs, TFLs and other spreadsheets, protocols, SAPs, client briefs, templates, reference libraries, and pasted context.
Yes. You choose the evidence and review the document structure before drafting. You can apply relevant reporting guidance, add a client or journal template, edit the text directly, and accept or reject AI-proposed changes. 7Scholar assists the workflow; it does not lock the writer out of it.
7Scholar is designed to work with the tools medical writers already use. Bring references into the project, manage citations alongside the draft, and move the deliverable back to Microsoft Word with its references. EndNote-compatible workflows are part of the source-to-delivery experience.
The current focus is source-heavy publications and medical communications work: journal manuscripts, literature and evidence reviews, scientific content, and related deliverables. Regulatory workflows are a deliberate next area, so we will be direct about fit before you start a project.